The company is currently conducting a Phase II trial with its drug candidate Namodenoson for the treatment of 60 patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic
steatohepatitis.
Lead researcher Professor Jose Quiles Morales, from the University of Granada, said: "The alterations caused by the long-term consumption of sunflower and fish oils make the liver susceptible to non-alcoholic
steatohepatitis, a very serious disease that may act as a catalyst for other liver diseases such as cirrhosis and liver cancer.
Visit Non-alcoholic
Steatohepatitis Biomarkers Market by Biomarker Type (Apoptosis Biomarkers, Hepatic Fibrosis Biomarkers, Oxidative Stress Biomarkers, Serum Biomarkers) and End User (Academics and Research Institute, Diagnostic Laboratories, Pharma and CROs, and Hospitals) and Forecast 2017-2021 at https://www.
Investigators randomized 101 individuals with biopsy-proven nonalcoholic
steatohepatitis (NASH) and either prediabetes or type 2 diabetes to 18 months of 45 mg/day of pioglitazone or placebo, followed by an 18-month open-label phase of pioglitazone, in addition to a hypocaloric diet.
Prevalence of nonalcoholic fatty liver disease and nonalcoholic
steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.
Both studies involved people with nonalcoholic
steatohepatitis (NASH), an aggressive disease characterised by fat in the liver.
USPRwire, Sat Mar 14 2015] GlobalData's clinical trial report, "
Steatohepatitis Global Clinical Trials Review, H1, 2015" provides data on the
Steatohepatitis clinical trial scenario.
Hepatic oxidative stress plays a key role in the development of non-alcoholic
steatohepatitis (NASH), therefore, treatment approaches that address the antioxidant is helpful in the therapy of patients with NASH.
NAFLD represents a wide spectrum of liver damage ranging from simple non-alcoholic fatty liver (NAFL) to non-alcoholic
steatohepatitis (NASH), featuring steatosis, inflammation, cirrhosis, and hepatocellular carcinoma.
According to the firms, the facility will support the development of CVC for the treatment of nonalcoholic
steatohepatitis and for working capital and general corporate needs.
and Italy monitored the weight gain and development of nonalcoholic fatty liver disease and its progression to nonalcoholic
steatohepatitis in MSG-treated mice fed either a calorie-restricted or regular diet.
Editor's Note: Nonalcoholic fatty liver disease includes steatosis, nonalcoholic
steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma, and can result in death if left untreated.
